Celsion Corporation (CLSN): Price and Financial Metrics
CLSN Price/Volume Stats
| Current price | $1.96 | 52-week high | $15.75 |
| Prev. close | $1.96 | 52-week low | $1.80 |
| Day low | $1.93 | Volume | 67,900 |
| Day high | $2.00 | Avg. volume | 150,471 |
| 50-day MA | $2.23 | Dividend yield | N/A |
| 200-day MA | $4.30 | Market Cap | 13.91M |
CLSN Stock Price Chart Interactive Chart >
Celsion Corporation (CLSN) Company Bio
Celsion Corporation focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company was founded in 1982 and is based in Lawrenceville, New Jersey.
Latest CLSN News From Around the Web
Below are the latest news stories about CELSION CORP that investors may wish to consider to help them evaluate CLSN as an investment opportunity.
Celsion Corporation Announces Company Name Change to Imunon, Inc.New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Co |
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company’s IL-12 gene-mediate |
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person particip |
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceLAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel. Dr. Le Goff will pre |
H.C. Wainwright Keeps Their Buy Rating on Celsion (CLSN)E ratio of -0.15. |
CLSN Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -88.44% |
| 5-year | -94.44% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | -24.05% |
| 2020 | -58.42% |
| 2019 | 21.28% |
Continue Researching CLSN
Want to see what other sources are saying about Celsion CORP's financials and stock price? Try the links below:Celsion CORP (CLSN) Stock Price | Nasdaq
Celsion CORP (CLSN) Stock Quote, History and News - Yahoo Finance
Celsion CORP (CLSN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...